Business Context and Reporting Period
This Form 8-K is a current report filed by Cerecor Inc. (not Avalo Therapeutics, Inc.) on February 23, 2018, covering events occurring on February 16, 2018. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing is a current report regarding corporate events and does not contain specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for these items.
Material Changes
- Entry into Material Definitive Agreement: On February 16, 2018, the Company entered into a licensing and development agreement with Flamel Ireland Limited (a subsidiary of Avadel US Holdings, Inc.).
- Completion of Acquisition: On February 16, 2018, the Company closed the acquisition of certain pediatric products from various Avadel entities, including Avadel US Holdings, Inc., Avadel Pharmaceuticals (USA), Inc., Avadel Pediatrics, Inc., Avadel Therapeutics, LLC, and Avadel Pharmaceuticals PLC.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, management commentary on future performance, or a detailed risk assessment. It notes that financial statements of the acquired businesses and pro forma financial information will be filed as an amendment to this report no later than 71 calendar days after the required filing date, to the extent required.
Investor Verification Checklist
- Verify the details of the licensing and development agreement with Flamel Ireland Limited referenced in the February 12, 2018 Form 8-K.
- Review the Asset Purchase Agreement associated with the acquisition of Avadel's pediatric products.
- Monitor for the upcoming amendment to this Form 8-K containing the financial statements of the acquired businesses and pro forma financial information.
- Confirm the strategic rationale for acquiring pediatric products from Avadel entities.